Evidence map›Paper›PMID 31870098›Full record

Observational studyAsian Pacific journal of cancer prevention : APJCP2019

Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer.

Hanifeh Mirtavoos-Mahyari, Mohsen Ghadami, Adnan Khosravi, Zahra Esfahani-Monfared, Sharareh Seifi, Elaheh Motevaseli, Mihan Pourabdollah, Mohammadhossein Modarressi

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hanifeh Mirtavoos-MahyariDepartment of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran. Iran.
Mohsen GhadamiDepartment of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran. Iran.
Adnan KhosraviTobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences,Tehran, Iran.
Zahra Esfahani-MonfaredChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sharareh SeifiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Elaheh MotevaseliDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran. Iran.
Mihan PourabdollahChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammadhossein ModarressiDepartment of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran. Iran.
Shahid Beheshti University of Medical Sciences · IRMasih Daneshvari Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing knowledge about the molecular profile of tumors has led to personalized treatment for achieving better outcomes in patients with nonsmall cell lung cancer (NSCLC). Currently, finding exact somatic genomic changes of tumor has gained great importance. On the other hand, crescendoing needs to actual tumor tissue at different time points during cancer treatment may produce major discomfort for NSCLC patients. Tumor genomes can be reconstructed by information obtained from circulating cell-free deoxyribonucleic acid (cfDNA) of peripheral blood. cfDNA may be represented as a suitable alternative test  for epidermal growth factor receptor (EGFR) mutation detection in these patients. This study aimed to assess validity of cfDNA in somatic EGFR mutation identification in Iranian NSCLC cases.

methodsSomatic mutation of EGFR gene was studied in both tissue specimens and plasma. Then, mutations were detected by polymerase chain reaction(PCR) and sequencing.

resultsWe observed a high concordance (90%) between tissue samples and cfDNA for EGFR gene mutation.  The sensitivity, accuracy, and positive precision value were 90%, 90% and 100%, respectively. A false negative rate of 10% was also demonstrated in this study.

conclusionWe established sensitive methods for detecting EGFR gene mutation which may be very useful in clinical practice.<br />.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCirculating Tumor DNAErbB ReceptorsFalse Negative ReactionsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingRetrospective StudiesBiomarkers, TumorCirculating Tumor DNAEGFR protein, humanErbB ReceptorsCarcinoma, Non-Small-Cell LungCell Free DNAepidermal growth factor receptorMutation

Identifiers

PMID31870098
PMCPMC7173361
OpenAlexW2989658093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.